

Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*
KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

VOLUNTARY ANNOUNCEMENT

**COMPLETION OF PATIENT ENROLLMENT IN PHASE II CLINICAL TRIAL
OF KX-826 FOR TREATMENT OF ACNE VULGARIS IN CHINA**

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to update its shareholders and potential investors on the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) is pleased to announce that on 14 October 2022, the Company has completed the enrollment of 160 patients for its phase II clinical trial (the “**Phase II Clinical Trial**”) of pyrilitamide (“**KX-826**”), a potential first-in-class topical drug developed by the Group, in China for the treatment of acne vulgaris.

The Phase II Clinical Trial is a combined design of phase I and phase II clinical trials, which is a multicenter, randomized, double-blind and placebo-controlled clinical study designed to evaluate the safety and efficacy of the topical application of KX-826 (gel) for the treatment of patients with mild to moderate acne vulgaris. The primary endpoint is the treatment success rate in each group at the end of week 12 (according to the 5-point Investigator Global Assessment (“**IGA**”) scale, subjects whose IGA scale decreases by not less than two points to 0-1 are defined as “success”). The leading principal investigator (“**Leading PI**”) of the Phase II Clinical Trial is Professor Leihong Xiang from Huashan Hospital affiliated to Fudan University. The phase I clinical trial has demonstrated a preliminary positive safety and tolerability profile in terms of dose-escalation and multiple doses applications per day for local use.

KX-826 is an androgen receptor (“**AR**”) antagonist and a potential first-in-class topical drug for the treatment of androgenetic alopecia (“**AGA**”) and acne vulgaris. For the acne vulgaris indication, KX-826 (gel), a topical AR antagonist with a specific target, could inhibit the combination of androgen

receptor and androgen in hair follicle sebaceous glands that reduces sebum production, thereby treating acne vulgaris.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that KX-826 will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, 16 October 2022

As at the date of this announcement, the executive Directors are Dr. Youzhi Tong and Ms. Yan Lu; the non-executive Directors are Mr. Weipeng Gao, Ms. Geqi Wei and Mr. Chengwei Liu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

** For identification purpose only*